Skip to main content
NCBI home page
Springer logoLink to Springer
. 2024 Dec 11;64(1):171–172. doi: 10.1007/s40262-024-01458-0

Correction: Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal Cancer

Daping Zhang 1, Adekemi Taylor 2, Jie Janet Zhao 2, Christopher J Endres 1,3, Ariel Topletz-Erickson 1,✉
PMCID: PMC11762418  PMID: 39661316

Correction to: Clinical Pharmacokinetics (2024) 63:1477–1487 10.1007/s40262-024-01412-0

In Table 2 of this article, the Geometric mean (%CV) for Ctrough,ss (ng/mL) under the column headed “HER2+ mCRC, N = 68” was mistakenly listed as 405 (44.9) and should have been 197 (62.5). The Table 2 should have appeared as shown below.

Table 2.

Model-predicted pharmacokinetic parameters and steady-state exposure measures of tucatinib in healthy participants and patients with HER2+ mCRC and HER2+ mBC receiving a starting dose of 300 mg BID

HER2+ mBC
N = 52		 HER2+ mCRC
N = 68		 Healthy participants (300 mg BID)
N = 128
Median [min, max] Geometric mean (%CV) Median [min, max] Geometric mean (%CV) Median [min, max] Geometric mean (%CV)
AUCss (ng·h/mL) 5770 [2100, 14,200] 5620 (42.7) 3230 [1310, 9210] 3370 (48.7) 2730 [541, 5760] 2560 (42.3)
Cmax,ss (ng/mL) 759 [221, 1840] 747 (44.5) 402 [141, 960] 405 (44.9) 480 [59, 1120] 447 (43.8)
Ctrough,ss (ng/mL) 303 [102, 870] 288 (58.5) 188 [42.9, 675] 405 (44.9) 88.4 [20.3, 263] 84 (60.2)
Rac, AUC 1.94 [1.36, 4.59] 1.99 (26.4) 2.45 [1.38, 5.32] 2.51 (27.9) 1.34 [1.13, 2.38] 1.35 (11.3)
Rac, Cmax 1.59 [1.14, 3.99] 1.64 (24.9) 1.92 [1.16, 3.53] 1.95 (25.1) 1.19 [1.07, 2.12] 1.21 (8.72)
Rac, Ctrough 2.38 [1.49, 5.94] 1.64 (24.9) 2.96 [1.94, 6.81] 1.95 (25.1) 1.57 [1.23, 2.76] 1.63 (18.8)
CL/F (L/h) 52 [21.2, 143] 53.4 (42.7) 92.9 [32.6, 230] 89 (48.7) 110 [52.1, 555] 117 (42.3)
Vss/F (L) 838 [257, 2190] 903 (42.2) 2130 [1680, 4690] 829 (20.9) 752 [409, 5650] 793 (38)
T1/2, β (h) 16.2 [7.48, 58.9] 16.7 (41.6) 21.3 [11.9, 53.5] 23.1 (32.6) 8.76 [5.22, 21] 9.16 (32.4)
Open in a new tab

AUC area under the concentration–time curve, AUCss area under the concentration–time curve at steady state, BID twice daily, Cmax maximum concentration, Cmax,ss maximum concentration at steady-state, CL/F apparent clearance, Ctrough trough concentration, Ctrough,ss trough concentration at steady-state, CV coefficient of variation, h hour, HER2+ human epidermal growth factor 2 positive, max maximum, mBC metastatic breast cancer, mCRC metastatic colorectal cancer, min minimum, N number of participants, Rac accumulation ratio, T1/2, β terminal half-life, Vss/F apparent steady-state volume of distribution

Table 2.

Model-predicted pharmacokinetic parameters and steady-state exposure measures of tucatinib in healthy participants and patients with HER2+ mCRC and HER2+ mBC receiving a starting dose of 300 mg BID

HER2+ mBC
N = 52		 HER2+ mCRC
N = 68		 Healthy participants (300 mg BID)
N = 128
Median [min, max] Geometric mean (%CV) Median [min, max] Geometric mean (%CV) Median [min, max] Geometric mean (%CV)
AUCss (ng·h/mL) 5770 [2100, 14,200] 5620 (42.7) 3230 [1310, 9210] 3370 (48.7) 2730 [541, 5760] 2560 (42.3)
Cmax,ss (ng/mL) 759 [221, 1840] 747 (44.5) 402 [141, 960] 405 (44.9) 480 [59, 1120] 447 (43.8)
Ctrough,ss (ng/mL) 303 [102, 870] 288 (58.5) 188 [42.9, 675] 197 (62.5) 88.4 [20.3, 263] 84 (60.2)
Rac, AUC 1.94 [1.36, 4.59] 1.99 (26.4) 2.45 [1.38, 5.32] 2.51 (27.9) 1.34 [1.13, 2.38] 1.35 (11.3)
Rac, Cmax 1.59 [1.14, 3.99] 1.64 (24.9) 1.92 [1.16, 3.53] 1.95 (25.1) 1.19 [1.07, 2.12] 1.21 (8.72)
Rac, Ctrough 2.38 [1.49, 5.94] 1.64 (24.9) 2.96 [1.94, 6.81] 1.95 (25.1) 1.57 [1.23, 2.76] 1.63 (18.8)
CL/F (L/h) 52 [21.2, 143] 53.4 (42.7) 92.9 [32.6, 230] 89 (48.7) 110 [52.1, 555] 117 (42.3)
Vss/F (L) 838 [257, 2190] 903 (42.2) 2130 [1680, 4690] 829 (20.9) 752 [409, 5650] 793 (38)
T1/2, β (h) 16.2 [7.48, 58.9] 16.7 (41.6) 21.3 [11.9, 53.5] 23.1 (32.6) 8.76 [5.22, 21] 9.16 (32.4)
Open in a new tab

AUC area under the concentration–time curve, AUCss area under the concentration–time curve at steady state, BID twice daily, Cmax maximum concentration, Cmax,ss maximum concentration at steady-state, CL/F apparent clearance, Ctrough trough concentration, Ctrough,ss trough concentration at steady-state, CV coefficient of variation, h hour, HER2+ human epidermal growth factor 2 positive, max maximum, mBC metastatic breast cancer, mCRC metastatic colorectal cancer, min minimum, N number of participants, Rac accumulation ratio, T1/2, β terminal half-life, Vss/F apparent steady-state volume of distribution

Incorrect version

Correct version

The original article has been corrected.

Articles from Clinical Pharmacokinetics are provided here courtesy of Springer

RESOURCES